Hyderabad: Hyderabad-based Oasis Fertility, the third largest player in the in vitro fertilisation (IVF) segment, has been providing advanced fertility treatment using the latest technology and equipment. Kiran Gadela, co-founder & MD of Oasis Fertility shares with Telangana Today their future plans and growth prospects in Telangana and pan-India, particularly in tier-2 and tier-3 locations. Excerpts-
We have 17 full-fledged IVF centres and will be adding eight centres this fiscal and will take the number to 50 centres by 2024. We have six centres in Hyderabad alone and we will be adding two more in the coming year. We are present in seven States including Telangana, Andhra Pradesh, Tamil Nadu, Karnataka, Jharkhand, Gujarat, and Maharashtra. In Telangana, we will enter tier-2 and tier-3 cities such as Karimnagar and Miryalaguda soon. We also intend to spread our presence to tier-2 and tier-3 cities pan-India. We will add two centres in Tamil Nadu and five in Karnataka. We will expand our presence in Maharashtra, Madhya Pradesh and Odisha. We also plan to enter northern markets after three years.
Emergence of specialty
WHO research shows one in six couples globally has some degree of infertility problem. India collectively is doing 3,00,000 IVF cycles and the need is expected to be almost ten times. Certainly, IVF centres are set to grow in the country in the coming years. Growing lifestyle issues, stress and Polycystic Ovarian Disease are some of the major factors that are leading to infertility. Oasis is striving to fill the gaps in this segment.
Focus on research
We have trained over 50 embryologists in-house. We have invested significantly in simulator equipment so that the staff can learn and gain an edge in fertility treatment. Every week, we have training programmes that focus on scientific, clinic and management aspects. We have published several research papers on fertility both on the clinical and scientific fronts.
Capital for growth
Oasis Fertility is the first company to receive an institutional investment in an IVF chain in India, having received capital in 2016 from India Life Sciences Fund II. In the past five years, our investor has helped us scale our operations to what we are today. Having begun our operations in 2010, we have been growing at a compound annual growth rate of 40 per cent. With over 300 employees at present, we expect to reach 500 in the next two years, with about 60 people taking care of different core corporate functions. We are striving for centralised leadership and creating institutionalised processes across the organisation.
The company could look at acquisitions and foraying into Southeast Asia and Middle East. After reaching 50 centres in India, the company may look at fresh funding. Till then, internal accruals will be adequate to double our current network by 2024 within India. From 5,000 IVF cycles, we want to quadruple to 20,000 cycles by then. An IPO can be a by-product of what we are doing across all the aspects in 2-3 years’ time.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.